Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

por Hurvitz, Sara A., Caswell-Jin, Jennifer L., McNamara, Katherine L., Zoeller, Jason J., Bean, Gregory R., Dichmann, Robert, Perez, Alejandra, Patel, Ravindranath, Zehngebot, Lee, Allen, Heather, Bosserman, Linda, DiCarlo, Brian, Kennedy, April, Giuliano, Armando, Calfa, Carmen, Molthrop, David, Mani, Aruna, Chen, Hsiao-Wang, Dering, Judy, Adams, Brad, Kotler, Eran, Press, Michael F., Brugge, Joan S., Curtis, Christina, Slamon, Dennis J.
Publicado 2020